Orencia®
Understanding Orencia®
Orencia® (abatacept) is a biologic disease-modifying antirheumatic drug (DMARD) used to help regulate the immune system and reduce inflammation in autoimmune diseases. In these conditions, T-cells can become overactiveand attack healthy tissues. Orencia® works by blocking the CD80/CD86 signal required for T-cell activation, thereby reducing immune system overactivity. This targeted approach helps to prevent joint damage, decrease inflammation, and slow disease progression.
How Orencia® Works:
- Blocks CD80/CD86 signaling to prevent overactive T-cell activation.
- Reduces inflammation and prevents joint damage in autoimmune diseases.
- Slows disease progression by regulating the immune response.
FDA Approval:
- Orencia® (abatacept): Approved on December 23, 2005
For more information, please visit the Orencia® patient website and speak with your healthcare provider to determine if Orencia® is the right treatment option for you.
Referral Form: |
MANUFACTURER: Bristol Myers Squibb (BMS) |
CLASS: Selective T-cell Costimulation Modulator (CTLA-4-Ig Fusion Protein) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Given at weeks 0, 2, and 4, then every 4 weeks |
Length of infusion: About 30 mins |
FOR MORE INFORMATION: |
Related drugs
